已发表论文

Nifuratel,一种新的 STAT3 抑制剂,具有对付人胃癌细胞的有效活性

 

Authors Zheng HL, Hong H, Zhang LL, Cai X, Hu M, Cai YP, Zhou B, Lin JY, Zhao CG, Hu WL

Received 12 July 2017

Accepted for publication 25 September 2017

Published 1 November 2017 Volume 2017:9 Pages 565—572

DOI https://doi.org/10.2147/CMAR.S146173

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Professor Kenan Onel

Abstract: Activation of the signal transducer and activator of transcription 3 (STAT3) is observed in multiple cancer types, including gastric cancer, and represents a potential drug target for chemotherapy. Currently, clinically available small-molecule inhibitors targeting STAT3 are lacking. Here, we report that nifuratel, an antiprotozoal and antifungal drug, is a potent inhibitor of STAT3. We found that nifuratel significantly suppressed proliferation and induced apoptosis of gastric cancer cells. Studies of the mechanism of action of nifuratel indicated that it acts by inhibiting the constitutive and interleukin-6-induced STAT3 activation. Taken together, our findings demonstrate that nifuratel may be a novel, clinically accessible STAT3 inhibitor in gastric cancer cells.
Keywords: nifuratel, STAT3, gastric cancer, inhibitor, drug